TransCode Therapeutics, Inc. Share Price
Equities
RNAZ
US89357L3033
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5499 USD | +4.74% | +13.38% | -91.66% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 3.19M 266M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 10 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.85% |
1 day | +4.74% | ||
1 week | +13.38% | ||
Current month | -19.49% | ||
1 month | -16.67% | ||
3 months | -27.64% | ||
6 months | -96.70% | ||
Current year | -91.66% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 73 | 01/18/01 | |
Zdravka Medarova
FOU | Founder | 50 | 01/16/01 |
Susan Duggan
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Magda Marquet
BRD | Director/Board Member | 65 | 01/21/01 |
Philippe Calais
CHM | Chairman | 65 | 01/18/01 |
Erik Manting
BRD | Director/Board Member | 53 | 20/20/20 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 0.5499 | +4.74% | 725,735 |
25/24/25 | 0.525 | +19.35% | 1,265,990 |
24/24/24 | 0.4399 | -4.35% | 91,390 |
23/24/23 | 0.4599 | +0.20% | 102,184 |
22/24/22 | 0.459 | -5.36% | 280,503 |
Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-91.66% | 3.19M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- RNAZ Stock